eneboparatide

AstraZeneca boosts rare disease portfolio with $1.05B Amolyt acquisition
BioSpace
Thu, 03/14/24 - 11:38 am
AstraZeneca
M&A
Amolyt Pharma
eneboparatide
hypoparathyroidism